Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?

Systemic sclerosis (SSc) is a multisystem disorder with protean clinical manifestations and substantial patient-to-patient heterogeneity [1]. Skin fibrosis characteristically shows rapid progression during early-stage disease but then reaches a plateau phase followed by slow regression. Transforming growth factor-beta (TGF-β) plays a key role in initiating and sustaining fibroblast activation and myofibroblast differentiation in SSc [2]. Microarray-based expression profiling of SSc skin biopsies shows an association that a 'TGF-β-activated gene signature' is associated with extensive skin involvement [3]. Multiple physiologic mechanisms regulate TGF-β signaling to prevent excessive tissue remodeling and fibrosis. One important endogenous anti-fibrotic defense mechanism involves the peroxisome proliferator-activated receptor-gamma (PPAR-γ) pathway, which blocks TGF-β responses [4].

The nuclear receptor PPAR-γ, initially identified in adipose tissue, plays key roles in regulation of adipogenesis, insulin sensitivity, and energy homeostasis [5]. In addition to being expressed in adipocytes, PPAR-γ is expressed in endothelial cells, vascular smooth muscle cells, macrophages, and fibroblasts [4, 6]. Endogenous and diet-derived fatty acids and eicosanoids such as prostaglandin J₂ (PGJ₂) act as low-affinity natural PPAR-γ ligands, whereas the thiazolidenedione drugs are potent synthetic PPAR-γ agonists [7]. Recent studies identified an entirely novel function for PPAR-γ in regulation of matrix homeostasis [8]. Exposure of fibroblasts to pharmacological PPAR-γ ligands resulted in suppression of collagen synthesis, myofibroblast differentiation, and other TGF-β-induced fibrotic responses in vitro [4, 9, 10]. Moreover, treatment of mice with PPAR-γ agonists prevented and attenuated bleomycin-induced scleroderma in vivo [11]. The significance of the anti-fibrotic activity of PPAR-γ is highlighted by genetic targeting experiments that demonstrate constitutive collagen overexpression and excessive fibrogenesis in PPAR-γ-null fibroblasts in vitro and in vivo [12]. Importantly, PPAR-γ expression and activity are reduced in SSc skin biopsies and explanted fibroblasts and are inversely correlated with fibrogenic markers in the lesional skin [13, 14]. These observations suggest that impaired PPAR-γ expression or function underlies unopposed fibroblast activation and progression of fibrosis in SSc. Assessing PPAR-γ expression or activity therefore might be a novel approach for assessing fibrogenic activity in SSc.

Adiponectin is a 244-amino acid hormone secreted from white adipose tissue that regulates insulin sensitivity and energy balance. The adiponectin gene is located on chromosome 3q27, a susceptibility locus for diabetes and metabolic disorders. Adiponectin transcription is tightly regulated by PPAR-γ through direct binding to conserved cis-acting regulatory DNA elements. Circulating adiponectin is decreased in obesity and the metabolic syndrome, and levels are increased in mice and in humans after treatment with PPAR-γ agonist agents [15]. Since serum adiponectin levels faithfully mirror PPAR-γ activity, adiponectin is now increasingly used as a biomarker of efficacy for PPAR-γ therapy [15]. In view of the PPAR-γ defect seen in SSc, we hypothesized that circulating adiponectin might be reduced in some patients with SSc. We therefore determined adiponectin levels in 129 patients with well-characterized SSc and correlated levels with clinical and laboratory features of disease. The results reveal significantly reduced adiponectin levels in diffuse cutaneous SSc (dcSSc) patients with early-stage disease, inverse correlation with the extent of skin fibrosis, and rising levels that parallel improved skin scores over time.

As expected, serum adiponectin levels in both control subjects and SSc patients were positively correlated with age and negatively correlated with BMI. Moreover, adiponectin levels were significantly lower in males than females, as reported previously [17]. The median levels of adiponectin were 14.7 μg/mL (IQR 15.4) among patients with SSc and 15.3 μg/mL (IQR 11.2) in healthy controls (P = 0.49). While there were no significant differences in adiponectin levels between patients and controls when adjusted for differences in age, gender, and ethnicity, patients with dcSSc (n = 50) had significantly lower adiponectin levels (median 10.0 μg/mL, IQR 11.3) than those with lcSSc (n = 79, median 18.3 μg/mL, IQR 13.1, P < 0.001) (Figure 1a). Further analyses revealed significant differences in adiponectin levels between SSc patients with or without anti-centromere antibody: median 21.5 μg/mL (IQR 20.3) versus 13.3 μg/mL (IQR 14.8) (P = 0.015), respectively. When grouped according to disease duration, patients with disease in a relatively early stage (arbitrarily defined as fewer than 18 months from the first non-Raynaud manifestation, n = 25) had low adiponectin levels (median 9.6 μg/mL, IQR 8.5) in comparison with patients with disease in the late stage (defined as more than 36 months, n = 91) (median 17.1 μg/mL, IQR 15.3, P = 0.004) (Figure 1c). The lower levels of adiponectin in the early stage of disease, when progression of skin fibrosis is thought to be the most active, might reflect reduced tissue PPAR-γ activity. The differences in adiponectin levels were significant even when adjusted for age, gender, ethnicity, and BMI (P < 0.001).

The difference in adiponectin levels between patients with lcSSc and those with dcSSc suggested that adiponectin, as a marker of PPAR-γ signaling in the skin, might be correlated with skin fibrosis. Indeed, we demonstrated a weak but statistically significant inverse correlation between adiponectin levels and the extent of skin fibrosis (r = -0.261, n = 124, P = 0.003) (Figure 1b). This correlation persisted even when corrected for age, gender, ethnicity, and BMI. A more robust correlation between MRSS and adiponectin levels was seen in Scl-70-positive patients, suggesting the association of reduced PPAR-γ activity with active skin disease (Figure 1b). In contrast to the skin score, neither FVC nor DlCO or radiologic evidence of pulmonary fibrosis could be demonstrated to have a significant correlation with serum adiponectin levels (Additional files 1 and 2). The correlation of serum adiponectin levels with skin but not lung fibrosis points to potential differences in the pathomechanisms underlying fibrosis in these organs, and PPAR-γ has a more prominent role in skin fibrosis than in lung fibrosis.

To examine changes in adiponectin levels over time, serial serum samples that were from the same patients and that were separated by more than 10 months were examined in 27 patients. Eighteen received mycophenolate mofetil alone or in combination with methotrexate, and seven received no specific disease-modifying therapy ([18] and Additional file 3). The results of the longitudinal analysis indicated that changes in adiponectin levels over time were inversely correlated with changes in skin score during the same interval (r = -0.522, n = 27, P = 0.005) (Figure 2). There were no apparent differences in changes in skin score or adiponectin levels associated with specific treatments.

The adiponectin gene contains a conserved peroxisome proliferator responsive element (PPRE) that is targeted by activated PPAR-γ, resulting in ligand-dependent transcription [19]. To examine adiponectin regulation in mesenchymal cells, growth-arrested confluent normal human preadipocytes or dermal fibroblasts were incubated with the PPAR-γ ligand pioglitazone for 48 hours. The results of real-time qPCR analysis indicated increases of greater than threefold and greater than ninefold in adiponectin mRNA levels of pioglitazone-treated fibroblasts and preadipocytes, respectively (Figure 3a). Reduced levels of circulating adiponectin in patients with early-stage dcSSc suggested attenuated PPAR-γ signaling during active fibrogenesis. To explore this possibility, we examined adiponectin mRNA expression in lesional SSc skin biopsies. For this purpose, a published genome-wide expression profiling dataset comprising biopsies of the lesional (clinically affected) skin from 15 patients with early dcSSc and six patients with lcSSc was queried [16]. A significant correlation between adiponectin mRNA expression in the skin and MRSS was observed in the individual biopsies (r = -0.44, n = 21, P = 0.044) (Figure 3b).

Taken together, the present results provide support for the involvement of PPAR-γ in modulation of skin fibrogenesis in SSc and suggest that reduced adiponectin levels might reflect reduced PPAR-γ activity associated with active or progressive skin fibrosis. Defective PPAR-γ activity in SSc contributes to unopposed fibroblast activation and is implicated in pathogenesis [14]. Adiponectin production is tightly regulated by PPAR-γ, and its levels in the serum represent a robust biomarker of PPAR-γ activity [15]. We found significantly lower serum adiponectin levels in patients with dcSSc than in those with lcSSc, and levels were lowest in the early stage of disease, when fibrogenesis is presumed to be the most active. A gradual rise in the levels of adiponectin over time might parallel spontaneous or treatment-associated skin regression and may signal attenuation of fibrogenesis. The present studies did not compare adiponectin levels in SSc with those with other autoimune diseases. However, studies have shown that rheumatoid arthritis, systemic lupus erythematosus, and other immune and inflammatory disorders are generally associated with elevated serum adiponectin [20–24]. Thus, it is noteworthy that, in contrast, SSc is not associated with elevated adiponection, despite the chronic inflammation that is thought to be a hallmark of this disease [25].

The levels of adiponectin in the circulation reflect PPAR-γ signaling activity in mesenchymal cells [15]. Thus, reduced adiponectin levels and adiponectin gene expression in lesional tissue in SSc indicate reduced adiponectin production that results from the impaired PPAR-γ activity. Adiponectin directly suppresses fibroblast migration and myofibroblast differentiation and blocks TGF-β-induced fibrotic responses, including collagen synthesis [26]. Moreover, adiponectin-null mice show exaggerated fibrogenesis in the heart, liver, and kidneys, suggesting a potential anti-fibrotic role [27]. Whether adiponectin is simply a marker for PPAR-γ signaling or, in fact, mediates its anti-fibrotic activities is currently unknown.

In summary, this cross-sectional analysis indicates that the levels of the PPAR-γ-regulated adiponectin are reduced in early-stage dcSSc and are inversely correlated with the skin score. Moreover, rising levels of adiponectin over time correlate with improvement in skin score. Reduced adiponectin reflecting impaired PPAR-γ activity might signify unopposed fibroblast activation and serve as a biomarker for ongoing fibrogenesis. Two recent studies with fewer patients reported reduced adiponectin levels in Japanese patients with SSc [20, 28]. These findings are consistent with our present results with a significantly larger patient cohort of a different ethnic background. Taken together, the results provide a compelling case for a role of PPAR-γ activity in skin fibrosis in SSc and support the prospective evaluation of adiponectin as a biomarker of fibrogenic activity.